TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
114.00
+4.80 (4.40%)
At close: Apr 10, 2026, 4:00 PM EDT
112.24
-1.76 (-1.54%)
Pre-market: Apr 13, 2026, 4:06 AM EDT
TransMedics Group Revenue
In the year 2025, TransMedics Group had annual revenue of $605.49M with 37.13% growth. TransMedics Group had revenue of $160.76M in the quarter ending December 31, 2025, with 32.18% growth.
Revenue (ttm)
$605.49M
Revenue Growth
+37.13%
P/S Ratio
6.46
Revenue / Employee
$674,269
Employees
898
Market Cap
3.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 605.49M | 163.95M | 37.13% |
| Dec 31, 2024 | 441.54M | 199.92M | 82.74% |
| Dec 31, 2023 | 241.62M | 148.16M | 158.53% |
| Dec 31, 2022 | 93.46M | 63.20M | 208.83% |
| Dec 31, 2021 | 30.26M | 4.62M | 18.03% |
| Dec 31, 2020 | 25.64M | 2.04M | 8.62% |
| Dec 28, 2019 | 23.60M | 10.59M | 81.33% |
| Dec 29, 2018 | 13.02M | 5.33M | 69.38% |
| Dec 30, 2017 | 7.69M | -5.33M | -40.96% |
| Dec 31, 2016 | 13.02M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bruker | 3.44B |
| Bio-Rad Laboratories | 2.58B |
| Bio-Rad Laboratories | 2.58B |
| Integer Holdings | 1.85B |
| LivaNova | 1.39B |
| Haemonetics | 1.32B |
| Neogen | 870.56M |
| iRhythm Holdings | 747.14M |
TMDX News
- 6 weeks ago - TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results - PRNewsWire
- 6 weeks ago - TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 7 weeks ago - TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 7 weeks ago - TransMedics to Present at Upcoming March Investor Conferences - PRNewsWire
- 2 months ago - TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - PRNewsWire
- 2 months ago - TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial - PRNewsWire
- 2 months ago - These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More - Benzinga
- 3 months ago - These under-the-radar stocks combine fast growth with big upside potential - Market Watch